Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Erlotinib in Advanced NSCLC
NCT01027598Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2010
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Started Jan 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01027598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027598.